Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Smith AD
The other half initiated treatment with DPP-4 inhibitors during that period
It must be an and." Quick summary: Part 2 Reminder of Part 1 Prevalence & Demand: Single largest patient population of any chronic disease in the country Traditionally marginalized groups are more affected by it The numbers are growing Patients want a solution desperately Clinical Efficacy: Clinical trial data suggests benefits outweigh risks for certain patient populations Actions of healthcare providers suggest they strongly want patients to have access Pricing Timeline: Branded drug will start with monopolistic prices for ~decade The patent will eventually expire The bigger the market (outlined above), the more competition, the greater the percentage price decrease Take away from Part 1: over a long enough time period, the price will come down given high demand, regulatory precedent, and economic incentives
: Bypasses digestion for immediate absorption and maximum effectiveness
US$ 28.59
US$ 24.86
US$ 29.88
